| abstract |
The present invention provides the use of VAV3 protein, or of an isoform thereof, especially VAV3var2 protein, or of VAV3 mRNA, or of a transcript variant thereof, especially VAV3var2 mRNA, as a cancer marker, especially for ovarian cancer or endometrial cancer, as well as a use of an anti-VAV3var2 antibody. Further, a method relating to VAV3, for treatment decisions in regard to platinum-based chemotherapy, taxane-based chemotherapy and anti-angiogenic chemotherapy is provided as well as a method to screen for candidate therapeutic compounds, relating to VAV3var2. |